human HT29 cells |
Proliferation assay |
|
|
|
Antiproliferative activity against human HT29 cells in serum containing medium |
18620382 |
human A375P cells |
Proliferation assay |
|
|
|
Antiproliferative activity against human A375P cells in serum containing medium |
18620382 |
human HN5 cells |
Proliferation assay |
|
|
|
Antiproliferative activity against human HN5 cells in serum containing medium |
18620382 |
HUVEC |
Function assay |
1 μM |
6 h |
|
Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 0.1 uM after 6 hrs by Matrigel assay |
24036042 |
HT-29 |
Function assay |
|
14 to 24 hrs |
|
Inhibition of RIPK1 in human HT-29 cells assessed as reduction in TNFalpha-induced necroptosis incubated for 14 to 24 hrs in presence of Smac mimetic and z-VAD-FMK by cell titer glo-based luminescence assay, IC50=0.873μM |
31622096 |
SJ-GBM2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
BT-12 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells |
29435139 |
Rh18 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells |
29435139 |
U-2 OS |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells |
29435139 |
Rh41 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells |
29435139 |
HUVEC |
Function assay |
100 nM |
2 hrs |
|
Inhibition of VEGF-stimulated VEGFR2 phosphorylation in human HUVEC cells at 100 nM preincubated for 2 hrs followed by VEGF stimulation by Western blot analysis |
29787262 |
HUVEC |
Antiangiogenic assay |
0.1 uM |
6 hrs |
|
Antiangiogenic activity in human HUVEC cells assessed as reduction in capillary-like tubular network formation at 0.1 uM after 6 hrs by phase-contrast microscopy |
29787262 |
EoL-1-cell |
Growth inhibition assay |
|
|
|
Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50=0.0000289μM |
SANGER |
AN3-CA |
Growth inhibition assay |
|
|
|
Inhibition of human AN3-CA cell growth in a cell viability assay, IC50=0.01005μM |
SANGER |
CGTH-W-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50=0.04001μM |
SANGER |
GDM-1 |
Growth inhibition assay |
|
|
|
Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=0.10399μM |
SANGER |
A204 |
Growth inhibition assay |
|
|
|
Inhibition of human A204 cell growth in a cell viability assay, IC50=0.10906μM |
SANGER |
G-402 |
Growth inhibition assay |
|
|
|
Inhibition of human G-402 cell growth in a cell viability assay, IC50=0.53184μM |
SANGER |
MFE-296 |
Growth inhibition assay |
|
|
|
Inhibition of human MFE-296 cell growth in a cell viability assay, IC50=0.59022μM |
SANGER |
NOS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=0.65987μM |
SANGER |
KG-1 |
Growth inhibition assay |
|
|
|
Inhibition of human KG-1 cell growth in a cell viability assay, IC50=0.71755μM |
SANGER |
HT55 |
Growth inhibition assay |
|
|
|
Inhibition of human HT55 cell growth in a cell viability assay, IC50=0.98781μM |
SANGER |
MG-63 |
Growth inhibition assay |
|
|
|
Inhibition of human MG-63 cell growth in a cell viability assay, IC50=1.00146μM |
SANGER |
CCF-STTG1 |
Growth inhibition assay |
|
|
|
Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50=1.04981μM |
SANGER |
RT-112 |
Growth inhibition assay |
|
|
|
Inhibition of human RT-112 cell growth in a cell viability assay, IC50=1.10376μM |
SANGER |
MC-IXC |
Growth inhibition assay |
|
|
|
Inhibition of human MC-IXC cell growth in a cell viability assay, IC50=1.11512μM |
SANGER |
HUTU-80 |
Growth inhibition assay |
|
|
|
Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=1.28103μM |
SANGER |
MV-4-11 |
Growth inhibition assay |
|
|
|
Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=1.34501μM |
SANGER |
LCLC-103H |
Growth inhibition assay |
|
|
|
Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50=1.44549μM |
SANGER |
G-401 |
Growth inhibition assay |
|
|
|
Inhibition of human G-401 cell growth in a cell viability assay, IC50=1.46421μM |
SANGER |
A704 |
Growth inhibition assay |
|
|
|
Inhibition of human A704 cell growth in a cell viability assay, IC50=1.60323μM |
SANGER |
ESS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human ESS-1 cell growth in a cell viability assay, IC50=1.60396μM |
SANGER |
HLE |
Growth inhibition assay |
|
|
|
Inhibition of human HLE cell growth in a cell viability assay, IC50=1.63804μM |
SANGER |
NY |
Growth inhibition assay |
|
|
|
Inhibition of human NY cell growth in a cell viability assay, IC50=1.84821μM |
SANGER |
A427 |
Growth inhibition assay |
|
|
|
Inhibition of human A427 cell growth in a cell viability assay, IC50=1.98075μM |
SANGER |
SK-N-DZ |
Growth inhibition assay |
|
|
|
Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=2.02381μM |
SANGER |
J82 |
Growth inhibition assay |
|
|
|
Inhibition of human J82 cell growth in a cell viability assay, IC50=2.06088μM |
SANGER |
GI-1 |
Growth inhibition assay |
|
|
|
Inhibition of human GI-1 cell growth in a cell viability assay, IC50=2.22951μM |
SANGER |
NCI-H716 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H716 cell growth in a cell viability assay, IC50=2.31633μM |
SANGER |
SF126 |
Growth inhibition assay |
|
|
|
Inhibition of human SF126 cell growth in a cell viability assay, IC50=2.47459μM |
SANGER |
H4 |
Growth inhibition assay |
|
|
|
Inhibition of human H4 cell growth in a cell viability assay, IC50=2.51262μM |
SANGER |
LB831-BLC |
Growth inhibition assay |
|
|
|
Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50=2.54566μM |
SANGER |
HCC1395 |
Growth inhibition assay |
|
|
|
Inhibition of human HCC1395 cell growth in a cell viability assay, IC50=2.58156μM |
SANGER |
LK-2 |
Growth inhibition assay |
|
|
|
Inhibition of human LK-2 cell growth in a cell viability assay, IC50=2.64569μM |
SANGER |
G-361 |
Growth inhibition assay |
|
|
|
Inhibition of human G-361 cell growth in a cell viability assay, IC50=3.04082μM |
SANGER |
NCI-H2342 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50=3.13316μM |
SANGER |
SK-LU-1 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=3.18767μM |
SANGER |
IGROV-1 |
Growth inhibition assay |
|
|
|
Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=3.24713μM |
SANGER |
EB2 |
Growth inhibition assay |
|
|
|
Inhibition of human EB2 cell growth in a cell viability assay, IC50=3.28168μM |
SANGER |
CAL-54 |
Growth inhibition assay |
|
|
|
Inhibition of human CAL-54 cell growth in a cell viability assay, IC50=3.28367μM |
SANGER |
OCUB-M |
Growth inhibition assay |
|
|
|
Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=3.31368μM |
SANGER |
LB1047-RCC |
Growth inhibition assay |
|
|
|
Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=3.53164μM |
SANGER |
Daudi |
Growth inhibition assay |
|
|
|
Inhibition of human Daudi cell growth in a cell viability assay, IC50=3.66219μM |
SANGER |
A172 |
Growth inhibition assay |
|
|
|
Inhibition of human A172 cell growth in a cell viability assay, IC50=3.7379μM |
SANGER |
KGN |
Growth inhibition assay |
|
|
|
Inhibition of human KGN cell growth in a cell viability assay, IC50=4.06709μM |
SANGER |
SNG-M |
Growth inhibition assay |
|
|
|
Inhibition of human SNG-M cell growth in a cell viability assay, IC50=4.08669μM |
SANGER |
SW1710 |
Growth inhibition assay |
|
|
|
Inhibition of human SW1710 cell growth in a cell viability assay, IC50=4.47318μM |
SANGER |
Daoy |
Growth inhibition assay |
|
|
|
Inhibition of human Daoy cell growth in a cell viability assay, IC50=4.77949μM |
SANGER |
DMS-273 |
Growth inhibition assay |
|
|
|
Inhibition of human DMS-273 cell growth in a cell viability assay, IC50=4.96202μM |
SANGER |
KU812 |
Growth inhibition assay |
|
|
|
Inhibition of human KU812 cell growth in a cell viability assay, IC50=5.37812μM |
SANGER |
NCI-H727 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50=5.40901μM |
SANGER |
P30-OHK |
Growth inhibition assay |
|
|
|
Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=5.4694μM |
SANGER |
MIA-PaCa-2 |
Growth inhibition assay |
|
|
|
Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50=5.60466μM |
SANGER |
TT |
Growth inhibition assay |
|
|
|
Inhibition of human TT cell growth in a cell viability assay, IC50=5.6624μM |
SANGER |
DK-MG |
Growth inhibition assay |
|
|
|
Inhibition of human DK-MG cell growth in a cell viability assay, IC50=5.72028μM |
SANGER |
GB-1 |
Growth inhibition assay |
|
|
|
Inhibition of human GB-1 cell growth in a cell viability assay, IC50=5.73434μM |
SANGER |
NCI-H520 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50=5.73435μM |
SANGER |
WM-115 |
Growth inhibition assay |
|
|
|
Inhibition of human WM-115 cell growth in a cell viability assay, IC50=5.75644μM |
SANGER |
CAL-72 |
Growth inhibition assay |
|
|
|
Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=5.9381μM |
SANGER |
NCI-H1573 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50=5.96542μM |
SANGER |
ES6 |
Growth inhibition assay |
|
|
|
Inhibition of human ES6 cell growth in a cell viability assay, IC50=6.02688μM |
SANGER |
TE-8 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-8 cell growth in a cell viability assay, IC50=6.16473μM |
SANGER |
GAMG |
Growth inhibition assay |
|
|
|
Inhibition of human GAMG cell growth in a cell viability assay, IC50=6.17776μM |
SANGER |
HGC-27 |
Growth inhibition assay |
|
|
|
Inhibition of human HGC-27 cell growth in a cell viability assay, IC50=6.2015μM |
SANGER |
CTV-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=6.20903μM |
SANGER |
NCI-H810 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50=6.31365μM |
SANGER |
NMC-G1 |
Growth inhibition assay |
|
|
|
Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=6.55237μM |
SANGER |
SNB75 |
Growth inhibition assay |
|
|
|
Inhibition of human SNB75 cell growth in a cell viability assay, IC50=6.56939μM |
SANGER |
SK-MES-1 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50=6.8663μM |
SANGER |
MZ2-MEL |
Growth inhibition assay |
|
|
|
Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50=6.93016μM |
SANGER |
TE-15 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-15 cell growth in a cell viability assay, IC50=7.16924μM |
SANGER |
S-117 |
Growth inhibition assay |
|
|
|
Inhibition of human S-117 cell growth in a cell viability assay, IC50=7.57924μM |
SANGER |
HuH-7 |
Growth inhibition assay |
|
|
|
Inhibition of human HuH-7 cell growth in a cell viability assay, IC50=7.69384μM |
SANGER |
CAS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=7.76339μM |
SANGER |
D-502MG |
Growth inhibition assay |
|
|
|
Inhibition of human D-502MG cell growth in a cell viability assay, IC50=7.78222μM |
SANGER |
IA-LM |
Growth inhibition assay |
|
|
|
Inhibition of human IA-LM cell growth in a cell viability assay, IC50=7.93364μM |
SANGER |
CAKI-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50=8.28831μM |
SANGER |
KYSE-70 |
Growth inhibition assay |
|
|
|
Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50=8.45447μM |
SANGER |
HCC1569 |
Growth inhibition assay |
|
|
|
Inhibition of human HCC1569 cell growth in a cell viability assay, IC50=8.46556μM |
SANGER |
SR |
Growth inhibition assay |
|
|
|
Inhibition of human SR cell growth in a cell viability assay, IC50=8.70202μM |
SANGER |
SH-4 |
Growth inhibition assay |
|
|
|
Inhibition of human SH-4 cell growth in a cell viability assay, IC50=8.73653μM |
SANGER |
SW954 |
Growth inhibition assay |
|
|
|
Inhibition of human SW954 cell growth in a cell viability assay, IC50=8.75347μM |
SANGER |
MPP-89 |
Growth inhibition assay |
|
|
|
Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=8.7782μM |
SANGER |
IST-MEL1 |
Growth inhibition assay |
|
|
|
Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50=8.91086μM |
SANGER |
EFM-19 |
Growth inhibition assay |
|
|
|
Inhibition of human EFM-19 cell growth in a cell viability assay, IC50=8.92276μM |
SANGER |
KS-1 |
Growth inhibition assay |
|
|
|
Inhibition of human KS-1 cell growth in a cell viability assay, IC50=8.97341μM |
SANGER |
786-0 |
Growth inhibition assay |
|
|
|
Inhibition of human 786-0 cell growth in a cell viability assay, IC50=8.99139μM |
SANGER |
SK-OV-3 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=9.01236μM |
SANGER |
C3A |
Growth inhibition assay |
|
|
|
Inhibition of human C3A cell growth in a cell viability assay, IC50=9.12939μM |
SANGER |
NCI-H358 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50=9.15929μM |
SANGER |
NCI-H2170 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50=9.20801μM |
SANGER |
HMV-II |
Growth inhibition assay |
|
|
|
Inhibition of human HMV-II cell growth in a cell viability assay, IC50=9.34065μM |
SANGER |
SW1088 |
Growth inhibition assay |
|
|
|
Inhibition of human SW1088 cell growth in a cell viability assay, IC50=9.56098μM |
SANGER |
RS4-11 |
Growth inhibition assay |
|
|
|
Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=9.71841μM |
SANGER |
SNU-423 |
Growth inhibition assay |
|
|
|
Inhibition of human SNU-423 cell growth in a cell viability assay, IC50=9.87712μM |
SANGER |
A431 |
Growth inhibition assay |
|
|
|
Inhibition of human A431 cell growth in a cell viability assay, IC50=9.88028μM |
SANGER |
BB65-RCC |
Growth inhibition assay |
|
|
|
Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=10.0298μM |
SANGER |
M059J |
Growth inhibition assay |
|
|
|
Inhibition of human M059J cell growth in a cell viability assay, IC50=10.2576μM |
SANGER |
Calu-3 |
Growth inhibition assay |
|
|
|
Inhibition of human Calu-3 cell growth in a cell viability assay, IC50=10.5161μM |
SANGER |
LAMA-84 |
Growth inhibition assay |
|
|
|
Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=10.6573μM |
SANGER |
ACHN |
Growth inhibition assay |
|
|
|
Inhibition of human ACHN cell growth in a cell viability assay, IC50=10.6743μM |
SANGER |
SW1990 |
Growth inhibition assay |
|
|
|
Inhibition of human SW1990 cell growth in a cell viability assay, IC50=10.7009μM |
SANGER |
LC-2-ad |
Growth inhibition assay |
|
|
|
Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50=10.7475μM |
SANGER |
U-698-M |
Growth inhibition assay |
|
|
|
Inhibition of human U-698-M cell growth in a cell viability assay, IC50=10.9926μM |
SANGER |
A2780 |
Growth inhibition assay |
|
|
|
Inhibition of human A2780 cell growth in a cell viability assay, IC50=11.0963μM |
SANGER |
VA-ES-BJ |
Growth inhibition assay |
|
|
|
Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50=11.1909μM |
SANGER |
A253 |
Growth inhibition assay |
|
|
|
Inhibition of human A253 cell growth in a cell viability assay, IC50=11.3911μM |
SANGER |
NCI-H2087 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50=11.7288μM |
SANGER |
NTERA-S-cl-D1 |
Growth inhibition assay |
|
|
|
Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50=11.7718μM |
SANGER |
TE-12 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-12 cell growth in a cell viability assay, IC50=11.8178μM |
SANGER |
LNCaP-Clone-FGC |
Growth inhibition assay |
|
|
|
Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50=12.358μM |
SANGER |
HT-1376 |
Growth inhibition assay |
|
|
|
Inhibition of human HT-1376 cell growth in a cell viability assay, IC50=12.3595μM |
SANGER |
LB2518-MEL |
Growth inhibition assay |
|
|
|
Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50=12.4325μM |
SANGER |
QIMR-WIL |
Growth inhibition assay |
|
|
|
Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=12.7363μM |
SANGER |
SF268 |
Growth inhibition assay |
|
|
|
Inhibition of human SF268 cell growth in a cell viability assay, IC50=12.9423μM |
SANGER |
MES-SA |
Growth inhibition assay |
|
|
|
Inhibition of human MES-SA cell growth in a cell viability assay, IC50=13.2346μM |
SANGER |
BPH-1 |
Growth inhibition assay |
|
|
|
Inhibition of human BPH-1 cell growth in a cell viability assay, IC50=13.2694μM |
SANGER |
CA46 |
Growth inhibition assay |
|
|
|
Inhibition of human CA46 cell growth in a cell viability assay, IC50=13.3899μM |
SANGER |
LB373-MEL-D |
Growth inhibition assay |
|
|
|
Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50=13.4353μM |
SANGER |
NCI-H1755 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50=13.5203μM |
SANGER |
NCI-H1581 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=13.742μM |
SANGER |
SNU-387 |
Growth inhibition assay |
|
|
|
Inhibition of human SNU-387 cell growth in a cell viability assay, IC50=13.9744μM |
SANGER |
HCC1419 |
Growth inhibition assay |
|
|
|
Inhibition of human HCC1419 cell growth in a cell viability assay, IC50=14.1325μM |
SANGER |
TE-9 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-9 cell growth in a cell viability assay, IC50=14.5343μM |
SANGER |
LCLC-97TM1 |
Growth inhibition assay |
|
|
|
Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50=14.5912μM |
SANGER |
BC-1 |
Growth inhibition assay |
|
|
|
Inhibition of human BC-1 cell growth in a cell viability assay, IC50=14.6038μM |
SANGER |
DU-145 |
Growth inhibition assay |
|
|
|
Inhibition of human DU-145 cell growth in a cell viability assay, IC50=14.7605μM |
SANGER |
KARPAS-45 |
Growth inhibition assay |
|
|
|
Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=15.1099μM |
SANGER |
SW684 |
Growth inhibition assay |
|
|
|
Inhibition of human SW684 cell growth in a cell viability assay, IC50=15.1418μM |
SANGER |
HCC2218 |
Growth inhibition assay |
|
|
|
Inhibition of human HCC2218 cell growth in a cell viability assay, IC50=15.1714μM |
SANGER |
EW-13 |
Growth inhibition assay |
|
|
|
Inhibition of human EW-13 cell growth in a cell viability assay, IC50=15.8055μM |
SANGER |
D-392MG |
Growth inhibition assay |
|
|
|
Inhibition of human D-392MG cell growth in a cell viability assay, IC50=15.8277μM |
SANGER |
PSN1 |
Growth inhibition assay |
|
|
|
Inhibition of human PSN1 cell growth in a cell viability assay, IC50=15.8665μM |
SANGER |
Saos-2 |
Growth inhibition assay |
|
|
|
Inhibition of human Saos-2 cell growth in a cell viability assay, IC50=15.9353μM |
SANGER |
COLO-679 |
Growth inhibition assay |
|
|
|
Inhibition of human COLO-679 cell growth in a cell viability assay, IC50=16.1233μM |
SANGER |
PC-14 |
Growth inhibition assay |
|
|
|
Inhibition of human PC-14 cell growth in a cell viability assay, IC50=16.4902μM |
SANGER |
CAL-85-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50=16.5837μM |
SANGER |
AU565 |
Growth inhibition assay |
|
|
|
Inhibition of human AU565 cell growth in a cell viability assay, IC50=16.7598μM |
SANGER |
A2058 |
Growth inhibition assay |
|
|
|
Inhibition of human A2058 cell growth in a cell viability assay, IC50=16.8504μM |
SANGER |
NH-12 |
Growth inhibition assay |
|
|
|
Inhibition of human NH-12 cell growth in a cell viability assay, IC50=17.5557μM |
SANGER |
Hs-578-T |
Growth inhibition assay |
|
|
|
Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50=17.6584μM |
SANGER |
RXF393 |
Growth inhibition assay |
|
|
|
Inhibition of human RXF393 cell growth in a cell viability assay, IC50=17.8039μM |
SANGER |
COLO-741 |
Growth inhibition assay |
|
|
|
Inhibition of human COLO-741 cell growth in a cell viability assay, IC50=18.1083μM |
SANGER |
NCI-H1355 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=18.1318μM |
SANGER |
GI-ME-N |
Growth inhibition assay |
|
|
|
Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50=18.453μM |
SANGER |
MEL-HO |
Growth inhibition assay |
|
|
|
Inhibition of human MEL-HO cell growth in a cell viability assay, IC50=18.9753μM |
SANGER |
SW982 |
Growth inhibition assay |
|
|
|
Inhibition of human SW982 cell growth in a cell viability assay, IC50=19.8406μM |
SANGER |
MONO-MAC-6 |
Growth inhibition assay |
|
|
|
Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50=19.9061μM |
SANGER |
MFH-ino |
Growth inhibition assay |
|
|
|
Inhibition of human MFH-ino cell growth in a cell viability assay, IC50=20.2037μM |
SANGER |
BEN |
Growth inhibition assay |
|
|
|
Inhibition of human BEN cell growth in a cell viability assay, IC50=20.3128μM |
SANGER |
HT-144 |
Growth inhibition assay |
|
|
|
Inhibition of human HT-144 cell growth in a cell viability assay, IC50=20.3697μM |
SANGER |
DoTc2-4510 |
Growth inhibition assay |
|
|
|
Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50=20.7966μM |
SANGER |
NCI-H522 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50=20.8971μM |
SANGER |
NCI-H1299 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50=21.167μM |
SANGER |
CAL-12T |
Growth inhibition assay |
|
|
|
Inhibition of human CAL-12T cell growth in a cell viability assay, IC50=21.2435μM |
SANGER |
CTB-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=21.6855μM |
SANGER |
COR-L105 |
Growth inhibition assay |
|
|
|
Inhibition of human COR-L105 cell growth in a cell viability assay, IC50=21.7949μM |
SANGER |
NCI-H1650 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50=21.8133μM |
SANGER |
SK-MEL-3 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=21.9788μM |
SANGER |
697 |
Growth inhibition assay |
|
|
|
Inhibition of human 697 cell growth in a cell viability assay, IC50=22.0402μM |
SANGER |
NEC8 |
Growth inhibition assay |
|
|
|
Inhibition of human NEC8 cell growth in a cell viability assay, IC50=22.1998μM |
SANGER |
ACN |
Growth inhibition assay |
|
|
|
Inhibition of human ACN cell growth in a cell viability assay, IC50=22.4965μM |
SANGER |
MHH-PREB-1 |
Growth inhibition assay |
|
|
|
Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50=22.5088μM |
SANGER |
RPMI-6666 |
Growth inhibition assay |
|
|
|
Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=22.5905μM |
SANGER |
BB30-HNC |
Growth inhibition assay |
|
|
|
Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=23.539μM |
SANGER |
HOS |
Growth inhibition assay |
|
|
|
Inhibition of human HOS cell growth in a cell viability assay, IC50=23.8014μM |
SANGER |
OVCAR-4 |
Growth inhibition assay |
|
|
|
Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=23.984μM |
SANGER |
SK-HEP-1 |
Growth inhibition assay |
|
|
|
Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50=24.0791μM |
SANGER |
OS-RC-2 |
Growth inhibition assay |
|
|
|
Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=24.0858μM |
SANGER |
MKN1 |
Growth inhibition assay |
|
|
|
Inhibition of human MKN1 cell growth in a cell viability assay, IC50=24.1401μM |
SANGER |
NCI-H510A |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50=24.5517μM |
SANGER |
DBTRG-05MG |
Growth inhibition assay |
|
|
|
Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50=25.014μM |
SANGER |
SW13 |
Growth inhibition assay |
|
|
|
Inhibition of human SW13 cell growth in a cell viability assay, IC50=25.0254μM |
SANGER |
HuO-3N1 |
Growth inhibition assay |
|
|
|
Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50=25.2535μM |
SANGER |
U-2-OS |
Growth inhibition assay |
|
|
|
Inhibition of human U-2-OS cell growth in a cell viability assay, IC50=25.5982μM |
SANGER |
PANC-10-05 |
Growth inhibition assay |
|
|
|
Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50=25.8389μM |
SANGER |
NUGC-3 |
Growth inhibition assay |
|
|
|
Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50=26.0051μM |
SANGER |
MZ1-PC |
Growth inhibition assay |
|
|
|
Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50=26.2821μM |
SANGER |
U-118-MG |
Growth inhibition assay |
|
|
|
Inhibition of human U-118-MG cell growth in a cell viability assay, IC50=26.3272μM |
SANGER |
NCI-H1703 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50=26.4593μM |
SANGER |
HT-1080 |
Growth inhibition assay |
|
|
|
Inhibition of human HT-1080 cell growth in a cell viability assay, IC50=26.6211μM |
SANGER |
EFO-21 |
Growth inhibition assay |
|
|
|
Inhibition of human EFO-21 cell growth in a cell viability assay, IC50=26.7536μM |
SANGER |
TK10 |
Growth inhibition assay |
|
|
|
Inhibition of human TK10 cell growth in a cell viability assay, IC50=27.1653μM |
SANGER |
ES1 |
Growth inhibition assay |
|
|
|
Inhibition of human ES1 cell growth in a cell viability assay, IC50=27.6673μM |
SANGER |
DMS-153 |
Growth inhibition assay |
|
|
|
Inhibition of human DMS-153 cell growth in a cell viability assay, IC50=28.2498μM |
SANGER |
KYSE-270 |
Growth inhibition assay |
|
|
|
Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50=28.3533μM |
SANGER |
MLMA |
Growth inhibition assay |
|
|
|
Inhibition of human MLMA cell growth in a cell viability assay, IC50=28.3719μM |
SANGER |
KURAMOCHI |
Growth inhibition assay |
|
|
|
Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50=28.5975μM |
SANGER |
NCI-H2347 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50=28.5994μM |
SANGER |
MCF7 |
Growth inhibition assay |
|
|
|
Inhibition of human MCF7 cell growth in a cell viability assay, IC50=28.7093μM |
SANGER |
HOP-92 |
Growth inhibition assay |
|
|
|
Inhibition of human HOP-92 cell growth in a cell viability assay, IC50=28.9327μM |
SANGER |
REH |
Growth inhibition assay |
|
|
|
Inhibition of human REH cell growth in a cell viability assay, IC50=28.9422μM |
SANGER |
RT4 |
Growth inhibition assay |
|
|
|
Inhibition of human RT4 cell growth in a cell viability assay, IC50=29.2259μM |
SANGER |
HT-1197 |
Growth inhibition assay |
|
|
|
Inhibition of human HT-1197 cell growth in a cell viability assay, IC50=29.2582μM |
SANGER |
BL-41 |
Growth inhibition assay |
|
|
|
Inhibition of human BL-41 cell growth in a cell viability assay, IC50=29.6923μM |
SANGER |
IST-MES1 |
Growth inhibition assay |
|
|
|
Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50=29.8144μM |
SANGER |
MOLT-16 |
Growth inhibition assay |
|
|
|
Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=30.3744μM |
SANGER |
GAK |
Growth inhibition assay |
|
|
|
Inhibition of human GAK cell growth in a cell viability assay, IC50=31.1007μM |
SANGER |
RD |
Growth inhibition assay |
|
|
|
Inhibition of human RD cell growth in a cell viability assay, IC50=31.2473μM |
SANGER |
COR-L23 |
Growth inhibition assay |
|
|
|
Inhibition of human COR-L23 cell growth in a cell viability assay, IC50=31.3023μM |
SANGER |
Capan-2 |
Growth inhibition assay |
|
|
|
Inhibition of human Capan-2 cell growth in a cell viability assay, IC50=31.6669μM |
SANGER |
ALL-PO |
Growth inhibition assay |
|
|
|
Inhibition of human ALL-PO cell growth in a cell viability assay, IC50=31.9592μM |
SANGER |
BCPAP |
Growth inhibition assay |
|
|
|
Inhibition of human BCPAP cell growth in a cell viability assay, IC50=32.4534μM |
SANGER |
OVCAR-3 |
Growth inhibition assay |
|
|
|
Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50=32.6497μM |
SANGER |
NKM-1 |
Growth inhibition assay |
|
|
|
Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=33.1404μM |
SANGER |
647-V |
Growth inhibition assay |
|
|
|
Inhibition of human 647-V cell growth in a cell viability assay, IC50=33.9321μM |
SANGER |
ES5 |
Growth inhibition assay |
|
|
|
Inhibition of human ES5 cell growth in a cell viability assay, IC50=34.9282μM |
SANGER |
A3-KAW |
Growth inhibition assay |
|
|
|
Inhibition of human A3-KAW cell growth in a cell viability assay, IC50=35.5285μM |
SANGER |
ChaGo-K-1 |
Growth inhibition assay |
|
|
|
Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50=35.5964μM |
SANGER |
NALM-6 |
Growth inhibition assay |
|
|
|
Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=35.6045μM |
SANGER |
8-MG-BA |
Growth inhibition assay |
|
|
|
Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=35.9586μM |
SANGER |
BL-70 |
Growth inhibition assay |
|
|
|
Inhibition of human BL-70 cell growth in a cell viability assay, IC50=36.8348μM |
SANGER |
MRK-nu-1 |
Growth inhibition assay |
|
|
|
Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50=37.0227μM |
SANGER |
COR-L88 |
Growth inhibition assay |
|
|
|
Inhibition of human COR-L88 cell growth in a cell viability assay, IC50=37.2976μM |
SANGER |
MDA-MB-415 |
Growth inhibition assay |
|
|
|
Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50=38.6783μM |
SANGER |
Becker |
Growth inhibition assay |
|
|
|
Inhibition of human Becker cell growth in a cell viability assay, IC50=39.1235μM |
SANGER |
NCI-H2452 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50=39.1445μM |
SANGER |
SW626 |
Growth inhibition assay |
|
|
|
Inhibition of human SW626 cell growth in a cell viability assay, IC50=39.1841μM |
SANGER |
SAS |
Growth inhibition assay |
|
|
|
Inhibition of human SAS cell growth in a cell viability assay, IC50=39.5476μM |
SANGER |
DMS-53 |
Growth inhibition assay |
|
|
|
Inhibition of human DMS-53 cell growth in a cell viability assay, IC50=39.7553μM |
SANGER |
CP66-MEL |
Growth inhibition assay |
|
|
|
Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50=39.7602μM |
SANGER |
NCI-H2405 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50=40.1926μM |
SANGER |
MC-CAR |
Growth inhibition assay |
|
|
|
Inhibition of human MC-CAR cell growth in a cell viability assay, IC50=40.2471μM |
SANGER |
CAL-120 |
Growth inhibition assay |
|
|
|
Inhibition of human CAL-120 cell growth in a cell viability assay, IC50=40.9723μM |
SANGER |
GCT |
Growth inhibition assay |
|
|
|
Inhibition of human GCT cell growth in a cell viability assay, IC50=41.2626μM |
SANGER |
A375 |
Growth inhibition assay |
|
|
|
Inhibition of human A375 cell growth in a cell viability assay, IC50=41.5395μM |
SANGER |
MEG-01 |
Growth inhibition assay |
|
|
|
Inhibition of human MEG-01 cell growth in a cell viability assay, IC50=41.6116μM |
SANGER |
NCI-H2122 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50=41.97μM |
SANGER |
RPMI-2650 |
Growth inhibition assay |
|
|
|
Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50=43.4784μM |
SANGER |
8305C |
Growth inhibition assay |
|
|
|
Inhibition of human 8305C cell growth in a cell viability assay, IC50=43.7675μM |
SANGER |
NCI-H1395 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50=44.1055μM |
SANGER |
EW-16 |
Growth inhibition assay |
|
|
|
Inhibition of human EW-16 cell growth in a cell viability assay, IC50=44.1094μM |
SANGER |
T98G |
Growth inhibition assay |
|
|
|
Inhibition of human T98G cell growth in a cell viability assay, IC50=44.4245μM |
SANGER |
IST-SL2 |
Growth inhibition assay |
|
|
|
Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50=44.9279μM |
SANGER |
NCI-H1651 |
Growth inhibition assay |
|
|
|
Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50=45.9208μM |
SANGER |
COR-L279 |
Growth inhibition assay |
|
|
|
Inhibition of human COR-L279 cell growth in a cell viability assay, IC50=46.2081μM |
SANGER |
YT |
Growth inhibition assay |
|
|
|
Inhibition of human YT cell growth in a cell viability assay, IC50=46.5067μM |
SANGER |
TE-11 |
Growth inhibition assay |
|
|
|
Inhibition of human TE-11 cell growth in a cell viability assay, IC50=46.7404μM |
SANGER |
C-33-A |
Growth inhibition assay |
|
|
|
Inhibition of human C-33-A cell growth in a cell viability assay, IC50=46.8197μM |
SANGER |
OVCAR-5 |
Growth inhibition assay |
|
|
|
Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50=47.2307μM |
SANGER |
PANC-03-27 |
Growth inhibition assay |
|
|
|
Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50=47.3513μM |
SANGER |
CaR-1 |
Growth inhibition assay |
|
|
|
Inhibition of human CaR-1 cell growth in a cell viability assay, IC50=48.2474μM |
SANGER |
SNU-449 |
Growth inhibition assay |
|
|
|
Inhibition of human SNU-449 cell growth in a cell viability assay, IC50=49.2285μM |
SANGER |